JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis
USA - NASDAQ:DERM - US48115J1097 - Common Stock
7.89 USD
+0.2 (+2.6%)
7.89 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to DERM. DERM was compared to 191 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DERM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
DERM had negative earnings in the past year.
In the past year DERM has reported a negative cash flow from operations.
In the past 5 years DERM reported 4 times negative net income.
In multiple years DERM reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of -10.77%, DERM is doing good in the industry, outperforming 65.44% of the companies in the same industry.
DERM's Return On Equity of -45.40% is in line compared to the rest of the industry. DERM outperforms 54.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.77% | ||
| ROE | -45.4% | ||
| ROIC | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DERM has a better Gross Margin (63.34%) than 71.73% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
DERM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
2. Health
2.1 Basic Checks
DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
DERM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DERM has been increased compared to 5 years ago.
The debt/assets ratio for DERM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.27, we must say that DERM is in the distress zone and has some risk of bankruptcy.
DERM's Altman-Z score of 0.27 is in line compared to the rest of the industry. DERM outperforms 52.36% of its industry peers.
DERM has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.11, DERM is doing worse than 73.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.27 |
ROIC/WACCN/A
WACC9.15%
2.3 Liquidity
A Current Ratio of 1.27 indicates that DERM should not have too much problems paying its short term obligations.
DERM has a worse Current ratio (1.27) than 77.49% of its industry peers.
A Quick Ratio of 0.95 indicates that DERM may have some problems paying its short term obligations.
The Quick ratio of DERM (0.95) is worse than 75.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
DERM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.41%, which is quite impressive.
Looking at the last year, DERM shows a very negative growth in Revenue. The Revenue has decreased by -29.11% in the last year.
DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.96% yearly.
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)-29.11%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.51%
3.2 Future
DERM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.90% yearly.
DERM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.03% yearly.
EPS Next Y68.5%
EPS Next 2Y53.13%
EPS Next 3Y47.9%
EPS Next 5YN/A
Revenue Next Year22.4%
Revenue Next 2Y33.35%
Revenue Next 3Y37.03%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 22.42, DERM is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DERM indicates a somewhat cheap valuation: DERM is cheaper than 75.39% of the companies listed in the same industry.
DERM's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.42 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DERM's earnings are expected to grow with 47.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.13%
EPS Next 3Y47.9%
5. Dividend
5.1 Amount
No dividends for DERM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.89
+0.2 (+2.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners32.43%
Inst Owner Change4.62%
Ins Owners16.12%
Ins Owner Change11.47%
Market Cap160.25M
Revenue(TTM)56.13M
Net Income(TTM)-8.74M
Analysts82
Price Target12.24 (55.13%)
Short Float %12.96%
Short Ratio13.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.85%
Min EPS beat(2)-49.39%
Max EPS beat(2)25.7%
EPS beat(4)2
Avg EPS beat(4)5.4%
Min EPS beat(4)-49.39%
Max EPS beat(4)58.28%
EPS beat(8)3
Avg EPS beat(8)54.6%
EPS beat(12)4
Avg EPS beat(12)29.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.7%
Min Revenue beat(2)-1.46%
Max Revenue beat(2)6.86%
Revenue beat(4)1
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-6.06%
Max Revenue beat(4)6.86%
Revenue beat(8)3
Avg Revenue beat(8)11.81%
Revenue beat(12)4
Avg Revenue beat(12)5.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.69%
PT rev (3m)28.57%
EPS NQ rev (1m)-58.33%
EPS NQ rev (3m)-1050%
EPS NY rev (1m)0.32%
EPS NY rev (3m)-22.73%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)-3.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.42 | ||
| P/S | 2.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)0.35
Fwd EY4.46%
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS2.78
BVpS0.95
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.77% | ||
| ROE | -45.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.34% | ||
| FCFM | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score2
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | 0.27 |
F-Score2
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y68.5%
EPS Next 2Y53.13%
EPS Next 3Y47.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.11%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.51%
Revenue Next Year22.4%
Revenue Next 2Y33.35%
Revenue Next 3Y37.03%
Revenue Next 5YN/A
EBIT growth 1Y-636.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.85%
EBIT Next 3Y84.38%
EBIT Next 5YN/A
FCF growth 1Y-35.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.59%
OCF growth 3YN/A
OCF growth 5YN/A
JOURNEY MEDICAL CORP / DERM FAQ
What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?
ChartMill assigns a fundamental rating of 3 / 10 to DERM.
What is the valuation status for DERM stock?
ChartMill assigns a valuation rating of 3 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.
What is the profitability of DERM stock?
JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.
Can you provide the financial health for DERM stock?
The financial health rating of JOURNEY MEDICAL CORP (DERM) is 1 / 10.